(Alliance News) - Hikma Pharmaceuticals PLC on Thursday increased its interim dividend following double-digit growth across the business in the first half. Chief Executive Officer Riad Mishlawi: "All of our businesses contributed to our strong performance, delivering 10% group revenue growth. Core operating profit is forecast to be within a USD700 million to USD730 million range, up from USD660 million from USD700 million. In 2023, Hikma delivered 14% year-on-year revenue growth and a core operating profit of GBP707 million. Hikma Pharmaceuticals shares were up 6.4% to 1,958.25 pence each in London on Thursday morning.

Source: The North Africa Journal August 08, 2024 16:37 UTC